WXXWY News and Press, Wuxi Biologics Cayman Inc ADR From 01/04/26

WuXi Biologics Achieves ISO 20400 Certification, Setting Benchmark in Sustainable Procurement PR Newswire WUXI, China , Jan. 4, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK) announced it has achieved ISO 20400 Sustainable Procurement certification, an internationally recogniz...

WuXi Biologics Recognized by Hong Kong ESG Reporting Awards 2025 for Outstanding ESG Disclosure PR Newswire HONG KONG , Dec. 23, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK) has once again raised the bar for sustainability commitment and transparency. The company has be...

WuXi Biologics Achieves CDP Highest "A" Ratings in Both Climate Change and Water Security PR Newswire SHANGHAI , Dec. 19, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK) announced that it has been named to the CDP "A" lists for both Climate Change and Water Security for 2025, u...

WuXi Biologics Extends Global CRDMO Network to Qatar Through Strategic MoU Signed with Qatar Free Zones Authority PR Newswire DOHA, Qatar , Dec. 2, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (C...

WuXi Biologics Included in Hang Seng Corporate Sustainability Benchmark Index PR Newswire The only company from pharmaceutical industry selected for inclusion in the Index Also included in HSI ESG Index and Hang Seng ESG 50 Index Green CRDMO solution provider with outstanding sus...

WuXi Biologics Honored with 2025 Global Customer Value Leadership Recognition by Frost & Sullivan WuXi Biologics Honored with 2025 Global Customer Value Leadership Recognition by Frost & Sullivan PR Newswire SHANGHAI , Oct. 20, 2025 /PRNewswire/ -- WuXi Biologics (2...

WuXi Biologics Receives MSCI AAA ESG Rating for Third Consecutive Year PR Newswire SHANGHAI , Oct. 9, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced it has rece...

WuXi Biologics Launches WuXia™4.0, Targeted Integration Cell Line Platform TrueSite TI™，to Accelerate Biologics Development with High Titer and Superior Stability PR Newswire TrueSite TI™, the fourth generation of WuXia™ cell line platfo...

WuXi Biologics Selected as Constituent of FTSE4Good Index Series for Fifth Consecutive Year PR Newswire SHANGHAI , Sept. 23, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), to...

Three WuXi Biologics Manufacturing Facilities Receive GMP Certification from Türkiye İlaç ve Tibbi Cihaz Kurumu (TITCK) PR Newswire WUXI, China , Sept. 17, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, De...